Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Eurasian Journal of Medicine and Oncology is a premier international journal established by KARE PUBL, dedicated to the exploration and advancement of knowledge within the fields of Internal Medicine and Oncology. Published in Turkey, this periodical offers a unique platform for researchers, healthcare professionals, and students to disseminate innovative research findings and clinical insights. With a commendable impact reflected in its 2023 Scopus rankings—ranking #49 in Internal Medicine and #143 in Oncology—this journal occupies a vital role in the academic and professional dialogue surrounding contemporary medical challenges. Operating under an Open Access framework, the journal facilitates broad dissemination of knowledge, ensuring that significant research is accessible to a global audience. The ongoing convergence of research and clinical application from 2019 to 2024 positions the Eurasian Journal of Medicine and Oncology as an essential resource for those committed to advancing the frontiers of medicine and oncology in an increasingly interconnected world.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

Welcome to the Canadian Journal of Respiratory Critical Care and Sleep Medicine, a prestigious peer-reviewed journal published by Taylor & Francis Inc. With an ISSN of 2474-5332 and an E-ISSN of 2474-5340, this journal serves as a vital platform for disseminating cutting-edge research in the fields of critical care, intensive care medicine, and pulmonary and respiratory medicine. Since its inception in 2017, the journal has established itself within the academic community, currently holding a Q2 ranking in Critical Care and Intensive Care Medicine and a Q3 ranking in Pulmonary and Respiratory Medicine for 2023. Although it operates under a standard access model, the journal remains committed to providing valuable insights and advancing knowledge through rigorous research articles, reviews, and case studies. Positioned in the heart of the United States, the journal aims to foster collaboration and innovation among healthcare professionals, researchers, and students dedicated to enhancing respiratory care and critical treatment protocols. Join us in exploring the dynamic intersection of research and practice that defines our mission.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.